GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (LTS:0HFQ) » Definitions » Loans Receivable

AnaptysBio (LTS:0HFQ) Loans Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is AnaptysBio Loans Receivable?

AnaptysBio's Loans Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


AnaptysBio Loans Receivable Historical Data

The historical data trend for AnaptysBio's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Loans Receivable Chart

AnaptysBio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AnaptysBio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AnaptysBio Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


AnaptysBio Loans Receivable Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

AnaptysBio Headlines

No Headlines